Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

BTK Inhibitor Combos Could Transform the Complex CLL Armamentarium

November 18th 2020

Alan P. Z. Skarbnik, MD, breaks down factors that should be kept in mind when navigating the complex chronic lymphocytic leukemia armamentarium as it relates to BTK inhibitors.

Dr. Awan on the Importance of Risk Stratification in CLL

November 17th 2020

Farrukh Awan, MD, discusses the importance of risk stratification in chronic lymphocytic leukemia.

Novel Agents Capture Attention in Newly Diagnosed CLL/SLL

November 17th 2020

Matthew Lunning, DO, discussed other key considerations for choosing treatments, continuous vs fixed-duration therapies, and emerging agents for patients with relapsed/ refractory CLL and SLL.

Dr. Ayers on Unmet Needs in CLL

November 16th 2020

Emily C. Ayers, MD, discusses unmet needs in chronic lymphocytic leukemia.

Dr. Danilov on the Role of Disease Biology in Up-front Treatment Selection in CLL

November 10th 2020

Alexey V. Danilov, MD, PhD, discusses the role of disease biology in up-front treatment selection in chronic lymphocytic leukemia.

Acalabrutinib Approved in Europe for Chronic Lymphocytic Leukemia

November 10th 2020

November 10, 2020 - The European Union approved the next-generation BTK inhibitor acalabrutinib for use in adult patients with chronic lymphocytic leukemia.

Dr. Lunning on Initial Treatment Considerations in CLL

November 10th 2020

Matthew A. Lunning, DO, discusses initial treatment considerations in chronic lymphocytic leukemia.

Treatment Selection in CLL Broadens Beyond Discussions of Efficacy

November 9th 2020

Alexey V. Danilov, MD, PhD, discusses BTK inhibitors and BCL-2 inhibitors that have led to a paradigm shift in the treatment of patients with chronic lymphocytic leukemia.

Dr. Awan on the Importance of Collaborative Care in CLL

November 4th 2020

Farrukh Awan, MD, discusses the importance of collaborative care in chronic lymphocytic leukemia.

Mato Presents Sequencing Framework for Crowded CLL Landscape

November 4th 2020

An explosion of therapeutic options for chronic lymphocytic leukemia has resulted in challenging questions about sequencing therapies for patients who progress after frontline treatment with little data to guide optimal therapy selection.

Dr. Davids on the Future of CAR T-Cell Therapy in CLL

October 27th 2020

Matthew S. Davids, MD, MMSc, discusses the future of CAR T-cell therapy in chronic lymphocytic leukemia.

Dr. Danilov on the Role of Chemoimmunotherapy in CLL

October 26th 2020

Alexey V. Danilov, MD, PhD, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Awan on Treatment Options in the First Relapsed Setting of CLL

October 23rd 2020

Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.

Dr. Skarbnik on Treatment Considerations in CLL

October 22nd 2020

Alan P. Z. Skarbnik, MD, discusses treatment considerations in chronic lymphocytic leukemia.

TP53 Mutations Among Prognostic Factors Associated With Ibrutinib-Resistant CLL

October 21st 2020

Patients with chronic lymphocytic leukemia who are at an increased risk of failure on ibrutinib can be identified prior to treatment initiation using a 4-factor prognostic model and considered for a clinical trial.

Dr. Bhat on ELEVATE-TN Results in Treatment-Naïve CLL

October 21st 2020

Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

FDA Grants Ublituximab/Umbralisib Combo Fast Track Status in CLL

October 21st 2020

The FDA has granted a fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the treatment of adult patients with chronic lymphocytic leukemia.

Dr. Skarbnik on Frontline Treatment Considerations in CLL

October 20th 2020

Alan P. Z. Skarbnik, MD, discusses frontline treatment considerations in chronic lymphocytic leukemia.

Dr. Bhat on the FDA Approval of Acalabrutinib in CLL

October 19th 2020

Seema A. Bhat, MD, discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase 3 ELEVATE-TN trial.

Dr. Bhat on the Potential for Time-Limited Combinations in CLL

October 15th 2020

Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.